Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hui Jun Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8870-6726; OpenAlex author ID A5100728329. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 6

  1. Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. Co-author DOI 10.1177/17588359261470681↗
  2. S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. Co-author DOI 10.1177/17588359251378698↗
  3. The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s11764-023-01429-7↗
  4. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenoca… Co-author DOI 10.1186/s12885-023-11464-3↗
  5. Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma. First author DOI 10.20892/j.issn.2095-3941.2023.0189↗
  6. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuejuan Cheng · 6 shared papers, 2022–2026 · strength 1.35
  2. Chunmei Bai · 6 shared papers, 2022–2026 · strength 1.35
  3. Tingting You · 4 shared papers, 2023–2026 · strength 0.99
  4. Yingyi Wang · 4 shared papers, 2022–2024 · strength 0.76
  5. Yingyi Wang · 2 shared papers, 2025–2026 · strength 0.59
  6. Huanwen Wu · 1 shared paper, 2025 · strength 0.26
  7. Zhou Zhu · 1 shared paper, 2023 · strength 0.20
  8. Menghua Dai · 1 shared paper, 2022 · strength 0.16
  9. Taiping Zhang · 1 shared paper, 2022 · strength 0.16
  10. Junchao Guo · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.